Zobrazeno 1 - 10 of 10 pro vyhledávání: '"Kyla Grimshaw"'
2
Abstract 5288: MPNST treatment and diagnosis in NF1: A health economic model
Autor: Hannah Mamuszka, Kyla Grimshaw, Erica Marie Marshall, Lydia Meyer Turkson
Publikováno v: Cancer Research. 78:5288-5288
Biomarkers have many applications along the care process in rare cancers and have potential to optimize treatment decisions. However, many diagnostic tests struggle to gain market access and appropriate value in terms of payer coverage because of a l
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce4170a1b7e2f6d99d1c0d039b76421d
https://doi.org/10.1158/1538-7445.am2018-5288
Zobrazit plný text záznamu
3
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth
Autor: T.G. Davies, Lisa Jane K. Hunter, Michelle D. Garrett, Matthias Reule, Timothy A. Yap, Lisa C A Seavers, Steven John Woodhead, Kyla Grimshaw, Lynsey Fazal, Neil T. Thompson, John Lyons, Paul Workman, Simon P. Heaton, Michael I. Walton, Victoria Lock
Publikováno v: Molecular cancer therapeutics. 9(5)
The serine/threonine kinase AKT plays a pivotal role in signal transduction events involved in malignant transformation and chemoresistance and is an attractive target for the development of cancer therapeutics. Fragment-based lead discovery, combine
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b18db0a9162a3f0e3bc7cd70c795c6c6
https://pubmed.ncbi.nlm.nih.gov/20423992
Zobrazit plný text záznamu
4
Abstract A148: Modeling patient responses to targeted therapy with rAAV mediated gene editing
Autor: Rachel Leah, Ruth Feltell, Christopher Torrance, Ramu Mangena, Annette S. Little, D P Gitterman, Holly Astley, Kyla Grimshaw, David Hughes, Jessica Hunt
Publikováno v: Molecular Cancer Therapeutics. 12:A148-A148
Successful drug development in oncology requires a deeper understanding of the functional consequences of the diverse genetic changes observed in human cancers. For example, responses to epidermal growth factor receptor (EGFR) inhibitors are observed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0cdab0794c09854ac6bfbada82dead25
https://doi.org/10.1158/1535-7163.targ-13-a148
Zobrazit plný text záznamu
5
Abstract B40: X-MANTM isogenic disease models: Precision tools for synthetic lethality screening
Autor: Markus Warmuth, Kyla Grimshaw, Agustin Chicas, Chris Torrance, Jessica Hunt, Jo Francis, Lihua Yu, Ping Zhu
Publikováno v: Molecular Cancer Therapeutics. 12:B40-B40
Cancer is a genetic disease, and as such, genetic variation is almost exclusively responsible for onset and progression, and critically is also a key component in an individual's response to therapeutics. Understanding the complex of genetics of canc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0ea4bf8a8afed92e72b89fb67f65f16
https://doi.org/10.1158/1535-7163.pms-b40
Zobrazit plný text záznamu
7
Abstract A70: Isogenic K-Ras mutant cancer cells: A novel platform for drug profiling
Autor: Federica Di Nicolantonio, Alberto Bardelli, Margherita Gallicchio, Jessica Hunt, Kyla Grimshaw, Zhiqiang Chen, Holly Astley, Chris Torrance, John Goodall, Claire Mahoney, Simona Lamba
Publikováno v: Molecular Cancer Therapeutics. 10:A70-A70
Ras mutations are present in approximately 49% of human colorectal cancers, with mutations in K-Ras G12 and G13 being the most common. Given their high prevalence, understanding how Ras mutations impact response to anticancer agents is crucial to the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37528676f68b54471ffae6f7079d21fd
https://doi.org/10.1158/1535-7163.targ-11-a70
Zobrazit plný text záznamu
8
Abstract A33: Metastasis score expression profiling of isogenic cell lines with defined oncogenic mutations and upon treatment with an inhibitor of PI3K/PTEN signaling pathway
Autor: Kyla Grimshaw, Alice Wang, Cindy Christopherson, John J. Sninsky, Shirley Kwok, Christopher Torrance, Sue Rigby
Publikováno v: Clinical Cancer Research. 16:A33-A33
Background: Human derived cell lines represent an important model system for fundamental research and translational medicine. We sought to gather patient-relevant information by examining a previously published metastasis score (MS) (proliferation in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f880b2dc354c6d5d151f90fbaf45da6c
https://doi.org/10.1158/1078-0432.tcmusa10-a33
Zobrazit plný text záznamu
9
Abstract 1651: The use of ‘X-MAN’ isogenic cell lines to define PI3-kinase inhibitor activity profiles
Autor: Chris Torrance, Kyla Grimshaw, Rebecca Foster, John Goodall, Suzanne Mead
Publikováno v: Cancer Research. 70:1651-1651
The tumour microenvironment promotes selective outgrowth of cells carrying mutations in oncogenes or tumour suppressors, enabling the activated pathways to drive tumour growth. Two such pathways are the PI3-K/AKT and RAS/RAF/MEK signaling pathways, w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d369d4980f4ee63ba23a2113b9f6d9c9
https://doi.org/10.1158/1538-7445.am10-1651
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje